Developing novel drugs for medulloblastoma
This research focuses on the development of novel drugs for the treatment of childhood brain tumours.
Developing and understanding new treatments for craniopharyngioma
Craniopharyngioma, a brain tumour affecting children, is difficult to treat. Work within the laboratories of the investigators has identified potential drugs that could turn off tumour growth. These drugs will be tested in patients whose tumours have regrown in a clinical trial.
Super-fit immune cells to seek and destroy bone cancer
Osteosarcoma bone cancer affects teenagers, around half of whom die within 5-years of diagnosis. We think we can solve these problems by modifying immune cells called “gamma-delta T-cells”.
‘ALL’ about metabolism: repurposing drugs for acute lymphoblastic leukaemia
Examining whether a group of drugs called gliflozins could be used to treat T-ALL
Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
What is helpful and what is unhelpful about remotely delivered acceptance and commitment therapy for young brain tumour survivors?
What helps and what hinders in remotely delivered acceptance and commitment therapy for survivors of childhood brain tumours: a diary and interview study.